Movement Disorders

Filter Your Results

 

News

 

First Patient Enrolled in Phase 3 Study of Troriluzole for Spinocerebellar Ataxia

Friday, March 15, 2019—The first patient has been enrolled in a phase 3 study (NCT03701399) of troriluzole (Biohaven, New Haven, CT) to treat spinocerebellar ataxia (SCA). The primary outcome measur…

Motor Function in Persons with REM Sleep Behavior Disorder Predictive of Conversion to Parkinson’s Disease

Tuesday, March 05, 2019—In a large multicenter study of 1,280 patients diagnosed with rapid eye movement (REM) sleep behavior disorder (RBD), published in Brain, patients’ scores on motor …

Verdiperstat, a Potential Treatment for Multiple System Atrophy, Granted Orphan Drug Status

Wednesday, February 20, 2019—The Food and Drug Administration has granted orphan drug status to verdiperstat (BHV-3241; Biohaven Pharmaceutical, New Haven, CT). Verdiperstat is a novel brain-penetrant mye…

Parkinson’s Foundation Hosting Conference on Use of Medical Marijuana

Thursday, February 14, 2019—On March 6-7, in Denver, CO, The Parkinson’s Foundation will host its first conference focused on the use of medical marijuana as potential therapy for patients with Par…

Wearable Device Provides Data for Treatment of Parkinson’s Disease

Wednesday, February 06, 2019—A study to be published in the Journal of Parkinson’s Disease and made available in prepress form shows that a wearable device (Personal KinetiGraph, Global Ki…

Novel Small Molecule PBT434 Receives Orphan Drug Designation for Treatment of Multiple System Atrophy

Friday, February 01, 2019—The Food and Drug Administration (FDA) has granted orphan drug designation for the molecule PBT434 (Prana Biotechnology LTD,Melbourne, Australia) as a potential treatment for …

First Patient Treated in Phase 3 Study of Ampreloxetine for Neurogenic Orthostatic Hypotension

Tuesday, January 29, 2019—The first patient has been dosed in a registrational phase 3 study (NCT03750552) of ampreloxetine (TD955; Theravance Biopharma, South San Francisco, CA) for treating symptomat…

Continuous Delivery of Levodopa May Decrease Motor Complications of OFF Time

Monday, January 28, 2019—A small open-label study, published in the journal Movement Disorders, compared the efficacy and pharmacokinetics of continuously administered oral levodopa/carbidopa (si…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC